 Scleroderma, Systemic
"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 2 | 0 | 2 | | 1993 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 4 | 0 | 4 | | 2001 | 2 | 1 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 0 | 1 | | 2007 | 4 | 0 | 4 | | 2008 | 4 | 0 | 4 | | 2009 | 3 | 2 | 5 | | 2010 | 3 | 0 | 3 | | 2012 | 2 | 1 | 3 | | 2013 | 3 | 1 | 4 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 4 | 0 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Lee MH, Bull TM. The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. F1000Res. 2019; 8.
-
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019 09; 54(3).
-
Li SC, Fuhlbrigge RC, Laxer RM, Pope E, Ibarra MF, Stewart K, Mason T, Becker ML, Hong S, Dedeoglu F, Torok KS, Rabinovich CE, Ferguson PJ, Punaro M, Feldman BM, Andrews T, Higgins GC. Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. Pediatr Rheumatol Online J. 2019 Jul 15; 17(1):43.
-
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 06 27; 380(26):2518-2528.
-
Jhajj A, Gill HP, Hague CJ, Murphy D, Elicker B, Soon J, Sulaiman N, Castillo-Saldana D, Wilcox PG, Dunne J, Lee JS, Wolters PJ, Ley B, Jones KD, Morisset J, Ryerson CJ. Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. Eur Respir J. 2019 05; 53(5).
-
Zhou Z, Fan Y, Tang W, Liu X, Thomason D, Zhou ZY, Macaulay D, Fischer A. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. J Rheumatol. 2019 08; 46(8):920-927.
-
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019 Jan 18; 20(1):13.
-
Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019 02; 71(2):182-195.
-
Stevens BE, Torok KS, Li SC, Hershey N, Curran M, Higgins GC, Moore KF, Egla Rabinovich C, Dodson S, Stevens AM. Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Arthritis Care Res (Hoboken). 2018 12; 70(12):1806-1813.
-
Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|